The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Recent Developments in Human Papillomavirus (HPV) Vaccinology
Open accessAbstract
Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV-16, which dominates the types causing cancer. There is also sufficient evidence that HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 cause cervical cancer. The L1 protein, which, when assembled into virus-like particles, induces HPV-type-specific neutralising antibodies, forms the basis of all commercial HPV vaccines. There are six licensed prophylactic HPV vaccines: three bivalent, two quadrivalent and one nonavalent vaccine. The bivalent vaccines protect from HPV types 16 and 18, which are associated with more than 70% of cervical cancers. Prophylactic vaccination targets children before sexual debut, but there are now catch-up campaigns, which have also been shown to be beneficial in reducing HPV infection and disease. HPV vaccination of adults after treatment for cervical lesions or recurrent respiratory papillomatosis has impacted recurrence. Gender-neutral vaccination will improve herd immunity and prevent infection in men and women. HPV vaccines are immunogenic in people living with HIV, but more research is needed on the long-term impact of vaccination and to determine whether further boosters are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Basu, P., Malvi, S. G., Joshi, S., Bhatla, N., Muwonge, R., Lucas, E., Verma, Y., Esmy, P. O., Poli, U. R. R., Shah, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00453-8 · Cited by 272
Denny, L., de Sanjose, S., Mutebi, M., Anderson, B. O., Kim, J., Jeronimo, J., Herrero, R., Yeates, K., Ginsburg, O., & Sankaranarayanan, R. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31795-0 · Cited by 246 · cited 1×
“These differences are primarily due to poor cervical cancer screening and treatment programmes [7].”
BackgroundEfficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women
Barnabas, R. V., Brown, E. R., Onono, M. A., Bukusi, E. A., Njoroge, B., Winer, R. L., Galloway, D. A., Pinder, L. F., Donnell, D., Wakhungu, I., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100056 · Cited by 223
The HIV epidemic in South Africa: Key findings from 2017 national population-based survey
Zuma, K., Simbayi, L., Zungu, N., Moyo, S., Marinda, E., Jooste, S., North, A., Nadol, P., Aynalem, G., Igumbor, E., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19138125 · Cited by 187 · cited 2×
“9 million), with young women carrying the burden of HIV incidence [89].”
BackgroundColzani, E., Johansen, K., Johnson, H., & Pastore Celentano, L. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2001659 · Cited by 86
Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies
Asangbeh-Kerman, S. L., Davidović, M., Taghavi, K., Kachingwe, J., Rammipi, K. M., Muzingwani, L., Pascoe, M., Jousse, M., Mulongo, M., Mwanahamuntu, M., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-13827-0 · Cited by 31
Metadata
- Authors
- Williamson, A.-L.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2023-06-26
- Volume
- 15
- Issue
- 7
- Pages
- 1440
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W4382281449
- Cited by
- 181
- References
- 8
- FWCI
- 30.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Developments in Human Papillomavirus (HPV) Vaccinology. https://app.cochat.ai/papers/10.3390/v15071440
- The paper
- Williamson, A.-L. (2023). Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. https://doi.org/10.3390/v15071440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.